Why is the Moderna-Merck melanoma vaccine attracting attention? GlobalData forecasts sales could exceed $1 billion by 2031 as late-stage trial results strengthen its outlook.
A personalized melanoma vaccine being developed by Moderna and Merck is moving closer to becoming one of the most closely watched cancer-vaccine programs, with sales forecast to surpass $1 billion by 2031, according to a GlobalData forecast. The projection comes as the companies advance the treatment through late-stage clinical development in melanoma.
The vaccine, called intismeran autogene (V940, formerly mRNA-4157), is different from conventional preventive vaccines. It is an individualized mRNA cancer vaccine, designed using mutations found in a patient’s own tumor. The treatment is being developed in combination with Merck’s immunotherapy pembrolizumab (Keytruda) for patients with high-risk melanoma after surgical removal of their tumors (1✔ ✔Trusted Source
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
).
Advertisement
How Does the Moderna-Merck Melanoma Vaccine Work?
The treatment is designed around the genetic characteristics of each patient’s cancer. After the melanoma is surgically removed, the tumor is analyzed to identify mutations that can produce cancer-specific targets known as neoantigens.
An individualized mRNA vaccine is then created to help the patient’s immune system recognize those targets. The vaccine can encode up to 34 tumor-specific neoantigens, allowing the immune system to mount a response against several features of the cancer rather than relying on a single target.
The approach is intended to complement pembrolizumab, which works by blocking the PD-1 pathway and helping immune cells maintain their ability to attack cancer cells.
A five-year analysis of the Phase 2b KEYNOTE-942 study, published in the Journal of Clinical Oncology in 2026, found that intismeran autogene combined with pembrolizumab reduced the risk of melanoma recurrence or death by 49% compared with pembrolizumab alone. The combination also reduced the risk of distant metastasis or death by 59% (2✔ ✔Trusted Source
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study
The analysis involved patients with high-risk stage III or IV melanoma whose tumors had been completely removed. At a median follow-up of 60.3 months, the improvement in recurrence-free survival remained evident. Researchers also reported an encouraging trend toward improved overall survival, although that analysis was exploratory and based on a limited number of events.
Advertisement
Phase 3 Results Put the Vaccine in the Spotlight
The melanoma vaccine reached another important milestone in August 2026. Moderna and Merck announced that their Phase 3 INTerpath-001 trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in recurrence-free survival when intismeran autogene was added to pembrolizumab. The combination also significantly delayed distant metastasis compared with pembrolizumab alone.
The trial enrolled 1,137 patients with high-risk melanoma following surgical removal of their tumors. The companies have not yet released the complete Phase 3 dataset, so detailed results on the magnitude of benefit, overall survival and other endpoints are still awaited.
The companies said no new safety concerns were identified in the initial analysis and plan to present the detailed findings at a future medical meeting before seeking regulatory discussions.
Advertisement
Why Is the Melanoma Vaccine Important?
Melanoma is an attractive setting for personalized cancer vaccines because melanoma cells can carry numerous mutations that may provide targets for the immune system.
The Moderna-Merck approach also illustrates how mRNA technology is moving beyond infectious diseases. Instead of creating one vaccine for a large population, the technology is being used to design a treatment around the molecular characteristics of an individual patient’s tumor.
The companies are also studying intismeran autogene in other cancers, including non-small cell lung cancer, bladder cancer and renal cell carcinoma, as part of a broader development program.
Manufacturing Could Still Be A Challenge
Personalization could be one of the biggest hurdles if the vaccine eventually reaches routine clinical use.
Unlike conventional vaccines that can be manufactured in large batches, each intismeran autogene treatment is designed for a specific patient. Tumor sequencing, identification of suitable mutations and production of the individualized vaccine all have to take place before treatment can be given.
That makes speed and manufacturing capacity important, particularly for patients whose disease could progress while they wait for their personalized treatment. The companies are therefore not only testing whether the vaccine works but also developing the manufacturing infrastructure needed to produce individualized doses at scale.
GlobalData Sees Major Commercial Potential
The clinical progress helps explain why the treatment has attracted significant commercial expectations. GlobalData forecasts that sales of Moderna and Merck’s melanoma vaccine could exceed $1 billion by 2031.
The forecast reflects expectations that a successful personalized cancer vaccine could establish a new treatment category, particularly if the Phase 3 findings are confirmed and regulators approve the therapy.
For now, however, intismeran autogene remains investigational and is not an approved melanoma vaccine. The full Phase 3 data and regulatory review will determine whether the promising clinical results can translate into an available treatment for patients.
References:
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma – (https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/)
- Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study – (https://ascopubs.org/doi/10.1200/JCO-26-00835)
Source-Medindia